Published: June 02, 2008

Transaction in Own Shares

Novo Nordisk A/S - Share repurchase programme

On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008.

Since the announcement as of 26 May 2008, the following transactions have been made under the programme:

                        Number of       Average     Transaction value,
                          shares       purchase                  DKK
                                         price
Accumulated, last       3,707,907                       1,204,217,638
announcement
19 May 2008                50,000      314.5200            15,726,500
20 May 2008                50,000      309.2000            15,460,000
21 May 2008                25,700      312.4000             8,028,680
22 May 2008                49,300      312.3100            15,396,883
23 May 2008                45,000      313.2700            14,097,150
Accumulated, 2008       3,927,907                       1,272,926,351

With the transactions stated above, Novo Nordisk owns a total of 28,591,990 treasury shares, corresponding to 4.4% of the share capital. The total amount of shares in the company is 646,960,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Stock Exchange Announcement no 31 / 2008